Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.’s Net Profit Rose 39% in First Three Quarters of 2021

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (上海复旦张江生物医药股份有限公司) (688505.SH) reported a net profit of 117.9 million yuan in the first three quarters of 2021, up 39% year-on-year.

Meanwhile, the company posted 698.1 million yuan in revenue, up 40.7% year-on-year.

At the end of the reporting period, it had 2.5 billion yuan in total assets and 478.4 million yuan in total liabilities, with a liability-to-asset ratio of 18.8%.

This article was automatically produced by Caixin Automation on Nov. 3, 2021.

Download our app to receive breaking news alerts and read the news on the go.

Follow the Chinese markets in real time with Caixin Global’s new stock database.